First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 804.62 USD -2.02% Market Closed
Updated: Jul 27, 2024
Have any thoughts about
Eli Lilly and Co?
Write Note

Intrinsic Value

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. [ Read More ]

The intrinsic value of one LLY stock under the Base Case scenario is 354.19 USD. Compared to the current market price of 804.62 USD, Eli Lilly and Co is Overvalued by 56%.

Key Points:
LLY Intrinsic Value
Base Case
354.19 USD
Overvaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eli Lilly and Co

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LLY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Eli Lilly Reports Strong Q1 Growth Driven by New Products
Earnings Call Summary

Eli Lilly Reports Strong Q1 Growth Driven by New Products

Eli Lilly's first quarter revenue increased by 26%, primarily due to the success of new products Mounjaro and Zepbound. Earnings per share rose by 59% to $2.58. The company saw significant growth in both the U.S. and international markets. Revenue in Europe and the rest of the world increased significantly, driven by strong demand and the approval of new delivery devices for Mounjaro. Despite some supply constraints, the company is optimistic about ramping up production in the second half of 2024. Eli Lilly also raised its full-year revenue guidance to $42.4 billion to $43.6 billion, reflecting its strong performance and growth prospects .

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eli Lilly and Co

Current Assets 25.2B
Cash & Short-Term Investments 2.6B
Receivables 10B
Other Current Assets 12.6B
Non-Current Assets 38.8B
Long-Term Investments 3.1B
PP&E 13.6B
Intangibles 11.7B
Other Non-Current Assets 10.3B
Current Liabilities 18.6B
Accounts Payable 2.5B
Accrued Liabilities 10.3B
Other Current Liabilities 5.9B
Non-Current Liabilities 32.5B
Long-Term Debt 24.6B
Other Non-Current Liabilities 8B
Efficiency

Earnings Waterfall
Eli Lilly and Co

Revenue
35.9B USD
Cost of Revenue
-7.1B USD
Gross Profit
28.8B USD
Operating Expenses
-17.5B USD
Operating Income
11.3B USD
Other Expenses
-5.2B USD
Net Income
6.1B USD

Free Cash Flow Analysis
Eli Lilly and Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

LLY Profitability Score
Profitability Due Diligence

Eli Lilly and Co's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
Negative Free Cash Flow
72/100
Profitability
Score

Eli Lilly and Co's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

LLY Solvency Score
Solvency Due Diligence

Eli Lilly and Co's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Average D/E
53/100
Solvency
Score

Eli Lilly and Co's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 936 USD with a low forecast of 606 USD and a high forecast of 1 155 USD.

Lowest
Price Target
606 USD
25% Downside
Average
Price Target
936 USD
16% Upside
Highest
Price Target
1 155 USD
44% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LLY?

Click here to dive deeper.

Competitive Landscape

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Price Appreciation

LLY Price
Eli Lilly and Co

1M 1M
-11%
6M 6M
+25%
1Y 1Y
+77%
3Y 3Y
+239%
5Y 5Y
+690%
10Y 10Y
+1 443%
Annual Price Range
804.62
52w Low
449.16
52w High
950.46
Price Metrics
Average Annual Return 38.37%
Standard Deviation of Annual Returns 19.64%
Max Drawdown -15%
Shares Statistics
Market Capitalization 766.7B USD
Shares Outstanding 900 404 992
Percentage of Shares Shorted 0.75%

LLY Return Decomposition
Main factors of price return

What is price return decomposition?

LLY News

Other Videos

Last Important Events
Eli Lilly and Co

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Eli Lilly and Co

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Eli Lilly and Co Logo
Eli Lilly and Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

766.7B USD

Dividend Yield

0.63%

Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

Contact

INDIANA
Indianapolis
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
+13172762000.0
https://www.lilly.com/

IPO

1970-07-09

Employees

35 000

Officers

Chairman, CEO & President
Mr. David A. Ricks
Executive VP & CFO
Ms. Anat Ashkenazi
EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Dr. Daniel M. Skovronsky M.D., Ph.D.
Executive VP, General Counsel & Secretary
Ms. Anat Hakim J.D.
Executive VP & President of Loxo
Mr. Jacob S. Van Naarden
Senior VP of Finance & Chief Accounting Officer
Mr. Donald A. Zakrowski
Show More
EVP & Chief Information and Digital Officer
Mr. Diogo Rau
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Alonzo Weems
Executive Vice President of Human Resources & Diversity
Mr. Eric Dozier
Senior VP & President of Elanco Animal Health
Mr. Jeffrey N. Simmons
Show Less

See Also

Discover More
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 354.19 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 804.62 USD, Eli Lilly and Co is Overvalued by 56%.